Spiriva: Tiotropium bromide (Spiriva) is indicated for the maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), the maintenance treatment of associated dyspnoea, and for prevention of exacerbations.
Spiriva Respimat: COPD: Tiotropium bromide (Spiriva Respimat) is indicated for the maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), the maintenance treatment of associated dyspnoea, the improvement of COPD compromised quality of life and reduction of exacerbations.
Asthma: Tiotropium bromide (Spiriva Respimat) is indicated as add-on maintenance treatment for the improvement of asthma symptoms, quality of life, and reduction of exacerbations in patients aged 6 years and older with asthma who remain symptomatic on at least inhaled corticosteroids.
Other Services
Country
Account